Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02592707|
Recruitment Status : Terminated (Terminated (Due to small number of ongoing patients. Patients ongoing at time of termination could choose to join study D-FR-01072-004 for long term follow-up.)
First Posted : October 30, 2015
Last Update Posted : March 31, 2022
- Study Details
- Tabular View
- Results Submitted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Neuroendocrine Tumors||Drug: Satoreotide tetraxetan Other: Amino acid solution Other: Antiemetic||Phase 1 Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||40 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||An International, Multicenter, Open-label Study to Evaluate Safety, Tolerability, Biodistribution, Dosimetry and Preliminary Efficacy of 177Lu-OPS201 for the Therapy of Somatostatin Receptor-positive Neuroendocrine Tumors (NETs)|
|Actual Study Start Date :||March 6, 2017|
|Actual Primary Completion Date :||February 22, 2022|
|Actual Study Completion Date :||February 22, 2022|
177Lu-OPS201 will be administered in 3 cycles at intervals of 8 weeks (+ up to 2 additional optional cycles)
Drug: Satoreotide tetraxetan
Satoreotide tetraxetan will be administered in 3 cycles at intervals of 8 weeks (+ up to 2 additional optional cycles)
Other Name: 177Lu-OPS201
Other: Amino acid solution
Given as an auxiliary product the day of the IMP infusion for safety reasons to protect the renal function.
Centres can use their established amino acid infusion or Ipsen amino acid solution (auxiliary medical product OPS301)
Other Name: OPS301
To counteract the known side effects of the amino acid infusion, such as nausea, dexamethasone (antiemetic) and as-required ondansetron will be administered 15 to 30 minutes before the start of the amino acid infusion (unless there are contraindications for these drugs).
- Safety and Tolerability of 177Lu-OPS201 assessed by number of patients with treatment related adverse events using CTCAE v5.0 [ Time Frame: during the whole study period of 34 months ]
- Area under the curve (AUC) of 177Lu-OPS201 per cycle in discernible thoracic and abdominal organs, target lesions and blood [ Time Frame: during the core study period of 10 months ]
- Maximal uptake (achieved in %) at the target lesions per cycle. [ Time Frame: during the core study period of 10 months ]
- Maximal uptake in discernible organs (%) and blood (%/mL) per cycle. [ Time Frame: during the core study period of 10 months ]
- Organs receiving the highest absorbed dose (Gy) for each cycle. [ Time Frame: during the core study period of 10 months ]
- Specific absorbed dose per organ (achieved in Gy/GBq) for each cycle. [ Time Frame: during the core study period of 10 months ]
- Cumulative absorbed organ doses (achieved in Gy). [ Time Frame: during the core study period of 10 months ]
- Preliminary therapeutic efficacy of 177Lu-OPS201 assessed by tumor response based on RECIST v1.1 [ Time Frame: during the whole study period of 34 months ]
- Preliminary therapeutic efficacy of 177Lu-OPS201 assessed by monitoring of PFS (based on RECIST v1.1 status) [ Time Frame: during the whole study period of 34 months ]
- Quality of Life (QoL) questionnaire [ Time Frame: during the core study period of 10 months ]
- Terminal half-life of radioactivity concentrations of the radiopharmaceutical in blood [ Time Frame: during the first 7 days of cycle 1 of the core study period ]
- PK parameters of OPS201, if OPS201 levels are measurable in plasma and urine. [ Time Frame: during the first 3 days of cycle 1 of the core study period ]PK parameters of OPS201(including, but not limited to, maximum observed concentration (Cmax), AUC, elimination half-life (t1/2), apparent total body clearance of the drug from plasma (CL), apparent volume of distribution (Vd), cumulative amount of unchanged drug excreted into the urine (Ae), renal clearance of the drug from plasma (CLR)) will be derived using the non-compartmental approach on the individual plasma concentration-time profiles of OPS201 and on the individual urine concentrations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Written informed consent.
- Patients of either gender, aged ≥ 18 years.
- Women of childbearing potential (not surgically sterile or less than 2 years postmenopausal) must use a medically accepted method of contraception and must agree to continue use of this method for the duration of the study and for 6 months after the last dose. Acceptable methods of contraception include abstinence, or double contraception: steroidal contraceptive (oral, transdermal, implanted, and injected) in conjunction with a barrier method (intrauterine device, condom etc.).
- Male patients must use a medically accepted method of contraception and must agree to continue use of this method for the duration of the study and for 6 months after the last activity administration.
- Karnofsky performance score ≥ 60.
- Life expectancy of at least 6 months.
Histologically confirmed diagnosis of -
- unresectable GEP NET (Grade I and Grade II according to WHO classification (2010, Annex 01), functioning and non-functioning).
- unresectable "typical lung carcinoid" or "atypical lung carcinoid" are acceptable (with the exception of Large Cell Bronchial Neuroendocrine Neoplasms and Small Cell Lung Cancers) (Caplin 2015).
- malignant, unresectable pheochromocytoma or paraganglioma
- Documentation of progressive disease based on RECIST v1.1 under prior anti-tumor therapy within 6 months of entry in the study (although the progression might have occurred more than 6 months before study entry). Patients should not have received further anti-tumor therapy once disease progression is documented. The images of this evaluation should be available for TGR evaluation.
- In countries where sunitinib or everolimus are marketed, patients with GEP NET and lung NET will be progressive under this prior anti-tumor treatment for the respective indication. Patients not suitable for everolimus/sunitinib therapy according to a tumor board decision (or comparable local practice) may also be enrolled into the study. Patients having everolimus/sunitinib therapy should have a wash-out phase of ≥ 4 weeks before the first treatment.
- Measurable disease based on RECIST v1.1.
- Confirmed presence of somatostatin receptors on technically evaluable tumor lesions documented by a positive Somatostatin Receptor Scan performed within 6 months prior to enrolment in the study.
- Calculated GFR ≥ 55 mL/min.
Blood test results as follows:
- Leukocytes: ≥ 4*10^9/L
- Erythrocytes: ≥ 3.5*12^9/L
- Platelets: ≥ 100*10^9/L
- Albumin: > 30 g/L
- ALT, AST, AP: ≤ 5 times ULN (upper limit of normal)
- Bilirubin: ≤ 2 times ULN (2x 1.1 mg/dL)
- Known hypersensitivity to 177Lu, to DOTA, to JR11 or to any of the excipients of 177Lu-OPS201.
- Any previous peptide receptor radionuclide therapy (PRRT).
- Diagnosis of thymic NET.
- Presence of active infection at screening or history of serious infection within the previous 6 weeks.
- Administration of any other investigational medicinal product within 60 days prior to entry.
- Prior or planned administration of a therapeutic radiopharmaceutical within 8 half-lives of the radionuclide including any time during the current study.
- Any extensive radiotherapy ≤ 3 months before enrolment.
- Chemotherapy ≤ 3 months before enrolment.
- Nephrectomy, renal transplant or concomitant nephrotoxic therapy putting the subject at high risk of renal toxicity during the study as assessed by the investigator.
- Pregnant or breast-feeding women: A pregnancy test will be performed at the start of the study for all female patients of childbearing potential (i.e. not surgically sterile or up to 2 years postmenopausal).
- Any uncontrolled significant medical, psychiatric or surgical condition (active infection, unstable angina pectoris, cardiac arrhythmia, poorly controlled hypertension, poorly controlled diabetes mellitus [HbA1c ≥9%], uncontrolled congestive heart disease, etc.) or laboratory findings that, in the opinion of the investigator, might jeopardize the patient's safety or that would limit compliance with the objectives and assessments of the study. Note: the patient should be able to tolerate high volume load.
- Current history of any malignancy other than NET within 5 years of enrolment except for fully -resected non-melanoma skin cancer or cervical cancer in situ. Current history of malignancy; patients with a secondary tumor in remission of > 5 years can be included
- Any mental condition rendering the patient unable to understand the nature, scope and possible consequences of the study, and/or evidence of an uncooperative attitude.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02592707
|United States, Texas|
|MD Anderson Cancer Center, Department of Nuclear Medicine|
|Houston, Texas, United States, 77030|
|Peter MacCallum Cancer Centre, Molecular Imaging and Targeted Therapeutics Laboratory|
|East Melbourne, Australia, 3002|
|Ramsay Hollywood Private Hospital, Department of Nuclear Medicine|
|Perth, Australia, 6009|
|University Hospital Vienna, Department of Nuclear Medicine|
|Vienna, Austria, 1090|
|CHU de Quebec - Universite Laval Research Center, Department of Radiology and Nuclear Medicine|
|Québec, Canada, G1R2J6|
|University Hospital Aarhus, Department of Hepatology and Gastroenterology|
|Aarhus, Denmark, 8000|
|CHU de Nantes, Hotel Dieu, Service de Medecine Nucleaire|
|Nantes, France, 44093|
|University Hospital Basel, Department of Nuclear Medicine|
|Basel, Switzerland, 4031|
|Royal Free Hospital, Department of Nuclear Medicine|
|London, United Kingdom, NW3 2QG|
|Study Director:||Ipsen Medical Director||Ipsen|
|Other Study ID Numbers:||
2015-002867-41 ( EudraCT Number )
OPS-C-001 ( Other Identifier: Initial sponsor study ID )
|First Posted:||October 30, 2015 Key Record Dates|
|Last Update Posted:||March 31, 2022|
|Last Verified:||March 2022|
|Studies a U.S. FDA-regulated Drug Product:||Yes|
|Studies a U.S. FDA-regulated Device Product:||No|
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid
Peripheral Nervous System Agents
Physiological Effects of Drugs
Hormones, Hormone Substitutes, and Hormone Antagonists
Antineoplastic Agents, Hormonal
Molecular Mechanisms of Pharmacological Action
Serotonin 5-HT3 Receptor Antagonists